The firm, which plans to trade under the ticker symbol CNTL, aims to carve out a larger market share by prioritizing Total Disc Replacement for cervical and lumbar procedures. Management frames this approach as a departure from traditional surgical techniques, positioning their hardware as a necessary evolution in spinal care.

Financial results reveal a volatile trajectory for the company. After posting $10.2 million in net income on $85.2 million in revenue for the first half of 2024, the business swung to a net loss of $503,000 on $60 million in revenue during the same period in 2025. Major stakeholders backing the transition to public markets include the Oman Investment Authority, AW Alpha Capital, and Viscogliosi Brothers.